1993
A phase II trial of mitomycin C, 5-fluorouracil and radiation therapy in the treatment of unresectable non-small cell lung cancer.
Murren J, Ganpule S, Papac R, Son Y, Peschel R, Durivage H, Buzaid A, Lamb L, Makuch R, Hait W. A phase II trial of mitomycin C, 5-fluorouracil and radiation therapy in the treatment of unresectable non-small cell lung cancer. Oncology Research Featuring Preclinical And Clinical Cancer Therapeutics 1993, 5: 53-7. PMID: 8395915.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerMedian survival timeMitomycin CComplete respondersLung cancerSurvival timeUnresectable stage III non-small cell lung cancerStage III non-small cell lung cancerUnresectable non-small cell lung cancerDay 1Concurrent mitomycin CPhase II trialOverall response rateX-irradiationModerate stomatitisSustained remissionII trialSplit courseWeek restMedian durationContinuous infusionSimultaneous administrationRadiation therapyResponse rate
1984
Predictive factors for tumor response to preoperative chemotherapy in patients with head and neck squamous carcinoma: The head and neck contracts program
Wolf G, Makuch R, Baker S. Predictive factors for tumor response to preoperative chemotherapy in patients with head and neck squamous carcinoma: The head and neck contracts program. Cancer 1984, 54: 2869-2877. PMID: 6208993, DOI: 10.1002/1097-0142(19841215)54:12<2869::aid-cncr2820541210>3.0.co;2-n.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBleomycinCarcinoma, Squamous CellCisplatinFemaleHead and Neck NeoplasmsHumansLymph NodesMalePrognosisConceptsSquamous cell carcinomaTumor responsePartial responsePreoperative chemotherapyComplete responseResponse rateTumor characteristicsCell carcinomaHigh tumor response ratesNeck squamous cell carcinomaNodal response ratesResectable stage IIIPatient performance statusPrimary tumor responseTumor response rateNational Cancer Institute trialsNeck squamous carcinomaVariety of patientsLarynx/Preoperative cisplatinChemotherapy regimenIntensive chemotherapyUntreated patientsAdvanced headPerformance status
1981
Preoperative Cisplatin and Bleomycin Therapy in Head and Neck Squamous Carcinoma: Prognostic Factors for Tumor Response
Baker S, Makuch R, Wolf G. Preoperative Cisplatin and Bleomycin Therapy in Head and Neck Squamous Carcinoma: Prognostic Factors for Tumor Response. JAMA Otolaryngology - Head & Neck Surgery 1981, 107: 683-689. PMID: 6170283, DOI: 10.1001/archotol.1981.00790470031008.Peer-Reviewed Original ResearchMeSH KeywordsBleomycinCarcinoma, Squamous CellCisplatinClinical Trials as TopicDrug Therapy, CombinationHead and Neck NeoplasmsHumansLymphatic MetastasisPreoperative CarePrognosisConceptsPrimary tumorInduction chemotherapyPreoperative cisplatinPartial responseComplete responseRegional adenopathyResectable stage IIISquamous cell carcinomaNational Cancer Institute trialsNeck squamous carcinomaPretreatment patientsPrognostic factorsBleomycin therapyNeck nodesSquamous carcinomaTumor characteristicsCell carcinomaPrognostic indicatorTumor responseRegional nodesBleomycin sulfateOral cavityStage IIIResponse rateChemotherapy
1980
Serum glycoproteins in cancer patients: First report of correlations with in vitro and in vivo parameters of cellular immunity
Baskies A, Chretien P, Weiss J, Makuch R, Beveridge R, Catalona W, Spiegel H. Serum glycoproteins in cancer patients: First report of correlations with in vitro and in vivo parameters of cellular immunity. Cancer 1980, 45: 3050-3060. PMID: 7388749, DOI: 10.1002/1097-0142(19800615)45:12<3050::aid-cncr2820451229>3.0.co;2-8.Peer-Reviewed Original ResearchConceptsDepressed cellular immunityLymphocyte reactivityCellular immunityCancer patientsAlpha 2 HS-glycoproteinAlbumin levelsTumor extentHS-glycoproteinVivo parametersLevels of haptoglobinLevels of APPSerum glycoprotein levelsSerum protein levelsSerum glycoproteinsOngoing trialsPreoperative patientsRegional tumorsSerum levelsImmune statusImmunologic functionSolid malignanciesNormal controlsPatientsGlycoprotein levelsPrimary site
1979
Serum glycoproteins in head and neck squamous carcinoma Correlations with tumor extent, clinical tumor stage, and T-cell levels during chemotherapy
Wolf G, Chretien P, Elias E, Makuch R, Baskies A, Spiegel H, Weiss J. Serum glycoproteins in head and neck squamous carcinoma Correlations with tumor extent, clinical tumor stage, and T-cell levels during chemotherapy. The American Journal Of Surgery 1979, 138: 489-500. PMID: 90464, DOI: 10.1016/0002-9610(79)90407-0.Peer-Reviewed Original ResearchConceptsΑ1-acid glycoprotein levelsT cell levelsTumor stageAcute phase proteinsUntreated patientsSerum levelsTumor extentCellular immunityImmune reactivitySquamous carcinomaPhase proteinsGlycoprotein levelsSpecific acute phase proteinsCompletion of chemotherapyClinical tumor stageChronic cigarette smokersΑ1-antitrypsin levelsΑ1-antitrypsinCellular immune parametersNeck squamous carcinomaPreoperative chemotherapyRecurrent carcinomaAlbumin levelsControl patientsRegional metastases